Chimeric antigen receptor modified T-cells for cancer treatment

T cells engineered with the chimeric antigen receptor (CAR) are rapidly emerging as an important immunotherapy for hematologic malignancies. The anti-cluster of differentiation (CD)19 CAR-T cell therapy has been remarkably successful against refractory/relapsed acute lymphoblastic leukemia (ALL), an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xiao Han, Yao Wang, Wei-Dong Han
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2018
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/5f052065f6bb40cbb3a2e894eb1bf860
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5f052065f6bb40cbb3a2e894eb1bf860
record_format	dspace
spelling	oai:doaj.org-article:5f052065f6bb40cbb3a2e894eb1bf8602021-12-02T13:27:57ZChimeric antigen receptor modified T-cells for cancer treatment2095-882X10.1016/j.cdtm.2018.08.002https://doaj.org/article/5f052065f6bb40cbb3a2e894eb1bf8602018-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X18300446https://doaj.org/toc/2095-882XT cells engineered with the chimeric antigen receptor (CAR) are rapidly emerging as an important immunotherapy for hematologic malignancies. The anti-cluster of differentiation (CD)19 CAR-T cell therapy has been remarkably successful against refractory/relapsed acute lymphoblastic leukemia (ALL), and a complete remission rate as high as 90% was observed, in both children and adults. Although the achievement of clinical efficacy using CAR-T cell therapy for solid tumors has encountered several obstacles that were associated with the multiple mechanisms contributing to an immunosuppressive microenvironment, investigators are exploring more optimized approaches to improve the efficiency of CAR-T in solid tumors. In addition, cytokine release syndrome (CRS) and neurotoxicity following CAR-T cell therapy can be severe or even fatal; therefore, the management of these toxicities is significant. Herein, we briefly review the structure of CAR-T and some novel CAR designs, the clinical application of CAR-T cell therapies, as well as the assessment and management of toxicities. Keywords: Chimeric antigen receptor T-cell, Hematologic malignancies, Solid tumor, ToxicitiesXiao HanYao WangWei-Dong HanKeAi Communications Co., Ltd.articleMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 4, Iss 4, Pp 225-243 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Xiao Han Yao Wang Wei-Dong Han Chimeric antigen receptor modified T-cells for cancer treatment
description	T cells engineered with the chimeric antigen receptor (CAR) are rapidly emerging as an important immunotherapy for hematologic malignancies. The anti-cluster of differentiation (CD)19 CAR-T cell therapy has been remarkably successful against refractory/relapsed acute lymphoblastic leukemia (ALL), and a complete remission rate as high as 90% was observed, in both children and adults. Although the achievement of clinical efficacy using CAR-T cell therapy for solid tumors has encountered several obstacles that were associated with the multiple mechanisms contributing to an immunosuppressive microenvironment, investigators are exploring more optimized approaches to improve the efficiency of CAR-T in solid tumors. In addition, cytokine release syndrome (CRS) and neurotoxicity following CAR-T cell therapy can be severe or even fatal; therefore, the management of these toxicities is significant. Herein, we briefly review the structure of CAR-T and some novel CAR designs, the clinical application of CAR-T cell therapies, as well as the assessment and management of toxicities. Keywords: Chimeric antigen receptor T-cell, Hematologic malignancies, Solid tumor, Toxicities
format	article
author	Xiao Han Yao Wang Wei-Dong Han
author_facet	Xiao Han Yao Wang Wei-Dong Han
author_sort	Xiao Han
title	Chimeric antigen receptor modified T-cells for cancer treatment
title_short	Chimeric antigen receptor modified T-cells for cancer treatment
title_full	Chimeric antigen receptor modified T-cells for cancer treatment
title_fullStr	Chimeric antigen receptor modified T-cells for cancer treatment
title_full_unstemmed	Chimeric antigen receptor modified T-cells for cancer treatment
title_sort	chimeric antigen receptor modified t-cells for cancer treatment
publisher	KeAi Communications Co., Ltd.
publishDate	2018
url	https://doaj.org/article/5f052065f6bb40cbb3a2e894eb1bf860
work_keys_str_mv	AT xiaohan chimericantigenreceptormodifiedtcellsforcancertreatment AT yaowang chimericantigenreceptormodifiedtcellsforcancertreatment AT weidonghan chimericantigenreceptormodifiedtcellsforcancertreatment
_version_	1718392977152278528

Chimeric antigen receptor modified T-cells for cancer treatment

Ejemplares similares